A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8<sup>+</sup> T-cell Responses, Impacting Tumor Challenge.

Duperret, Elizabeth K; Perales-Puchalt, Alfredo; Stoltz, Regina; G H, Hiranjith; Mandloi, Nitin; Barlow, James; Chaudhuri, Amitabha; Sardesai, Niranjan Y; Weiner, David B

A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8⁺ T-cell Responses, Impacting Tumor Challenge.

Duperret, Elizabeth K; Perales-Puchalt, Alfredo; Stoltz, Regina; G H, Hiranjith; Mandloi, Nitin; Barlow, James; Chaudhuri, Amitabha; Sardesai, Niranjan Y; Weiner, David B.

Affiliation

Duperret EK; The Wistar Institute, Vaccine and Immunotherapy Center, Philadelphia, Pennsylvania.
Perales-Puchalt A; The Wistar Institute, Vaccine and Immunotherapy Center, Philadelphia, Pennsylvania.
Stoltz R; The Wistar Institute, Vaccine and Immunotherapy Center, Philadelphia, Pennsylvania.
G H H; MedGenome Inc., Foster City, California.
Mandloi N; MedGenome Inc., Foster City, California.
Barlow J; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania.
Chaudhuri A; Geneos Therapeutics, Plymouth Meeting, Pennsylvania.
Sardesai NY; MedGenome Inc., Foster City, California.
Weiner DB; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania.

Cancer Immunol Res ; 7(2): 174-182, 2019 02.

Article de En | MEDLINE | ID: mdl-30679156

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Antigènes d'histocompatibilité de classe I / Lymphocytes T CD8/ / Déterminants antigéniques des lymphocytes T / Vaccins anticancéreux / Vaccins à ADN / Antigènes néoplasiques Limites: Animals Langue: En Journal: Cancer Immunol Res Année: 2019 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google